about
Neuroinflammation in the peripheral nerve: Cause, modulator, or bystander in peripheral neuropathies?First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathyRecommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosisInflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin.Modulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models.A New Folding Kinetic Mechanism for Human Transthyretin and the Influence of the Amyloidogenic V30M Mutation.A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis.Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis.Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretinGd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targetingGenetic Prion Disease Caused by PRNP Q160X Mutation Presenting with an Orbitofrontal Syndrome, Cyclic Diarrhea, and Peripheral NeuropathyAn Isolated Case of Late-onset Amyloidogenic Transthyretin Type Familial Amyloid Polyneuropathy Associated with a Mutant Transthyretin Substituting Methionine for Valine at Position 30 Showing Latent Progressive Cardiac Involvement Confirmed by SeriNeuromuscular issues in systemic disease.Drugs for the treatment of peripheral neuropathies.Cyclodextrins as Protective Agents of Protein Aggregation: An Overview.Advances in proteomic study of cardiac amyloidosis: progress and potential.Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.Genetic background modifies amyloidosis in a mouse model of ATTR neuropathy.Familial Amyloid Polyneuropathy Type IV (FINNISH) with Rapid Clinical Progression in an Iranian Woman: A Case ReportGreen tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational studyNovel Antibody for the Treatment of Transthyretin Amyloidosis.Transthyretin chemical chaperoning by flavonoids: Structure-activity insights towards the design of potent amyloidosis inhibitors.Life paths of patients with transthyretin-related familial amyloid polyneuropathy Val30Met: a descriptive study.Hydrolysis and Dissolution of Amyloids by Catabodies.Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation.Novel screening for transthyretin amyloidosis by using fat ultrasonography.Systemic amyloidoses and proteomics: The state of the art.Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis.Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case reportA FTIR microspectroscopy study of the structural and biochemical perturbations induced by natively folded and aggregated transthyretin in HL-1 cardiomyocytes
P2860
Q26801349-C31C37A9-2070-4FBE-AE0B-77CF92C44928Q28071522-81371406-102D-4174-A7D7-68CF61B0FB40Q28076550-EEFF4600-42F2-4548-8DD9-D81FA20205BFQ33685899-26BB11DD-7DD8-4747-ADE6-D6ED94CA5DB9Q35082885-A605C16F-8B8C-4C4D-BA7C-1D63F42F79A4Q36121846-BD4901D7-4E01-41CB-8362-0CA704E1C6D1Q36389712-06FABE1A-2B06-4CF5-853C-31143E6AFB62Q36919063-AAFD5F8C-0AE3-4419-85E8-E8631A25F7B3Q36981504-CE9F2E9B-143E-4C5E-8A1B-82F5ECE9A8F8Q37126036-BB968978-3D66-466B-A63D-3AAB8CE375D2Q37491711-4E86913B-F14E-4C47-BA12-4D535C700193Q37681076-DD05A3A5-479F-42A5-AF13-D617786BF935Q38501865-B150F3CD-6E7D-4406-AC72-FFC17461141DQ38633190-35BA3343-7DBF-49D1-81BB-ECD609C6BC6FQ38796247-BD67BEA1-FE61-48B6-A27C-4C573F0A13CCQ38809423-41DDB469-F606-4BC2-BCE8-B71AE099076BQ41282445-DC78524D-94A1-46A4-9678-FB020A6182CAQ41682728-284A7329-9A42-47D3-A81D-DF91B5F1D43FQ42111673-655E0ABF-71F7-48FA-84E1-90CD79395A79Q42162484-1234D0EB-618C-4A8E-8752-4AE7FCD8B36DQ45931013-0ECE2897-DA94-40BC-862D-77E26DC6FB76Q46693222-DBE7515D-A9AB-4A32-9805-77664F35A398Q47593376-3B58AD5F-043C-4146-973C-8A332A14FDF3Q48216989-F1652E89-4994-41FF-8BE6-7BFE664143D6Q49544433-AAEB303E-E881-4BA8-9E3C-68AE64A8BF32Q51107108-4F211AD1-EA14-4999-954F-A63224F8AB14Q55167558-2BDAEC92-D5FA-4CEC-ADC9-98FF20782129Q55280701-C343C949-91C6-4EDF-A939-E128659E8881Q58253415-08AEDB6F-9377-4CDA-9E09-8E9E8695D729Q58731093-584B35A1-1253-4C0B-ACE4-9271D00578BA
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Recent advances in transthyretin amyloidosis therapy
@ast
Recent advances in transthyretin amyloidosis therapy
@en
Recent advances in transthyretin amyloidosis therapy
@nl
type
label
Recent advances in transthyretin amyloidosis therapy
@ast
Recent advances in transthyretin amyloidosis therapy
@en
Recent advances in transthyretin amyloidosis therapy
@nl
prefLabel
Recent advances in transthyretin amyloidosis therapy
@ast
Recent advances in transthyretin amyloidosis therapy
@en
Recent advances in transthyretin amyloidosis therapy
@nl
P2860
P356
P1476
Recent advances in transthyretin amyloidosis therapy
@en
P2093
Mitsuharu Ueda
Yukio Ando
P2860
P2888
P356
10.1186/2047-9158-3-19
P577
2014-09-13T00:00:00Z
P5875
P6179
1034311946